Global Coronavirus Diagnostics

Coronavirus Diagnostics Comprehensive Study by Type (Molecular, Serology, Antigen-Based), Product Used (Instruments, Reagents & Kits), Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, HKU1-CoV, MERS-CoV), End-Users (Hospitals, Public Health Labs, Private or Commercial Labs, Physician Labs, Diagnostic Centers and Clinics, Research Institutes, Others), Sample Type (Nasopharyngeal (NP) Swab, Oropharyngeal (OP) Swab, Nasal Swab), Mode of Diagnosis (Point-of-Care (POC), Non-Point-of-Care (Non-PoC)) Players and Region - Global Market Outlook to 2032

Coronavirus Diagnostics Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Coronavirus Diagnostics
Covid-19 is an infectious disease caused by a newly discovered coronavirus. The name Covid-19 represents the virus's membership of the coronavirus family, with its first human interaction noted in 2019. Coronavirus is the term coined for the family of viruses that are transmitted between animals and humans. Hence they are also known as zoonotic viruses. In addition, the virus outbreak was confirmed on March 27, 2020, on six continents and in more than 197 countries. According to the World Health Organization (WHO), fever, fatigue and dry cough are common symptoms of Covid-19 infection. Other symptoms of the disease include shortness of breath, sore throat, pain, and diarrhea in some cases, as well as nausea or a runny nose. In addition, this infection can spread from one person to another through droplets of saliva, or it can leak out of the nose when an infected person coughs or sneezes. The time from a person's exposure to Covid-19 to the onset of symptoms is generally between two and fourteen days, with an average of five days. The current status of lead COVID testing is toward increasing capacity but mixed accuracy. For efficient and accurate COVID-19 diagnosis, doctors need a portable or on-site diagnostic test to be able to manage patients in real-time in the shortest possible time. This has encouraged the introduction of point-of-care (POC) tests for diagnosis, the primary aim of which is to cut test times from hours to minutes. The most common concern of the governments of all nations affected by Covid-19 is the intolerable need to screen and test large numbers of patients for possible Sars-Cov-2 infections. As a result, most of them face significant bottlenecks in the supply of diagnostic kits to test for the virus. Diagnostic virology companies have been under immense pressure so as to provide reliable test kits and also the demand for the in vitro or point-of-care testing capabilities in the laboratories in various countries is also increasing. However, with the introduction of automated SARS-CoV-2 test systems, the diagnosis increases its capacity to carry out such tests considerably. However, currently, only a few companies are focused on developing rapid immunoassay tests for Covid-19 diagnosis.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)


The companies are now exploring the market by adopting merger & acquisition, expansion, investments, a new development in existing products, and collaboration as their preferred strategies. The players are also exploring new geographies and industries through expansion and acquisition so as to avail a competitive advantage through combined strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Coronavirus Diagnostics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

F. Hoffmann-La Roche AG (Switzerland), Bio-Rad Laboratories Inc. (United States), Beckman Coulter Inc. (United States), Becton, Dickinson, and Company (United States), Lonza Group AG (Switzerland), Hologic, Inc. (United States), QIAGEN (Germany), GlaxoSmithKline Biologicals SA (Belgium), Abbott Laboratories (United States), Perkin Elmer, Inc. (United States), Neuberg Diagnostics (India), 1drop Inc. (Switzerland), Veredus Laboratories (Hong Kong), ADT Biotech (Malaysia), Quest Diagnostics (United States), LabCorp (United States), altona Diagnostics GmbH (Germany), bioMérieux SA (France) and Mylab Discovery Solutions Pvt Ltd. (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Aldatu Biosciences (United States), Quidel Corporation (United States), Luminex Corporation (United States) and Cepheid Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Coronavirus Diagnostics market by Type (Molecular, Serology and Antigen-Based) and Region.



On the basis of geography, the market of Coronavirus Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Product Used, the sub-segment i.e. Instruments will boost the Coronavirus Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Infection Type, the sub-segment i.e. HCoV-229E will boost the Coronavirus Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Users, the sub-segment i.e. Hospitals will boost the Coronavirus Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Sample Type, the sub-segment i.e. Nasopharyngeal (NP) Swab will boost the Coronavirus Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Mode of Diagnosis, the sub-segment i.e. Point-of-Care (POC) will boost the Coronavirus Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
A Shift in Focus from Centralized Laboratories to Decentralized Point-Of-Care Testing, An Upsurge in Validating and Developing Rapid POC Immunodiagnostic Tests to Facilitate Decentralized Testing and Growing Trend of Incorporation of Artificial Intelligence (AI) in the COVID-19 Tests for Rapid and Efficient Diagnosis

Market Growth Drivers:
The Increasing Global Prevalence of COVID-19, Unavailability of Specific Medicine or a Vaccine for the Coronavirus Disease, An Increase in the Need for Developing Diagnostic Tests Owing to the Global Conditions and The Increased Demand for Rapid Immunoassay Tests for Disease Diagnosis

Challenges:
Shortage of Medical Professionals That Have Sufficient Knowledge Regarding the Use of Diagnostic Kits for COVID-19

Restraints:
Lack of Awareness among Developing Countries Regarding the Necessary Precautions to Be Taken

Opportunities:
Growth in Funding For Research on Coronavirus Diagnostics, Increasing Application of Molecular Diagnostic Technologies in Pharmacogenetics and Point-Of-Care Testing and The Rise in Integration of Novel Technologies and Software Solutions with COVID-19 Testing

Market Leaders and their expansionary development strategies
On 19th March 2019, Baxter International Inc., a global leader in acute care, and bioMérieux, a world leader in the field of in-vitro diagnostics, announced an agreement to develop the future biomarkers with the goal to rapidly identify and inform the treatment of acute kidney injury (AKI). The announcement was made at the International Symposium on Intensive Care and Emergency Medicine (ISICEM).
In July 2020, Becton, Dickinson, and Company launched an on-site SARS-CoV-2 diagnostic test to respond to the growing need for rapid testing. This test enables real-time testing of patients with an easy-to-use, highly portable instrument.
The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have been addressing the challenges posed by the recent shortage of reagents in the United States. The FDA has approved various COVID-19 detection tests issued for emergencies (EUA). This strategy aims to relax various common standards so that market participants can apply for approval for their kits and reagents easily and quickly. This is expected to increase the range of kits and reagents. In addition, the FDA recently approved the use of a variety of swabs, particularly polyester swabs, to diagnose this infection. In April 2020, the FDA also announced that U.S. cotton had planned to manufacture polyester-based swabs in large quantities that could also be used to collect samples for coronavirus testing.

Key Target Audience
Providers of Coronavirus Diagnostics, Market Research Firms, Governmental Bodies, End-Users, Potential Investors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Molecular
  • Serology
  • Antigen-Based
By Product Used
  • Instruments
  • Reagents & Kits

By Infection Type
  • HCoV-229E
  • HCoV-OC43
  • SARS-CoV
  • HKU1-CoV
  • MERS-CoV

By End-Users
  • Hospitals
  • Public Health Labs
  • Private or Commercial Labs
  • Physician Labs
  • Diagnostic Centers and Clinics
  • Research Institutes
  • Others

By Sample Type
  • Nasopharyngeal (NP) Swab
  • Oropharyngeal (OP) Swab
  • Nasal Swab

By Mode of Diagnosis
  • Point-of-Care (POC)
  • Non-Point-of-Care (Non-PoC)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Increasing Global Prevalence of COVID-19
      • 3.2.2. Unavailability of Specific Medicine or a Vaccine for the Coronavirus Disease
      • 3.2.3. An Increase in the Need for Developing Diagnostic Tests Owing to the Global Conditions
      • 3.2.4. The Increased Demand for Rapid Immunoassay Tests for Disease Diagnosis
    • 3.3. Market Challenges
      • 3.3.1. Shortage of Medical Professionals That Have Sufficient Knowledge Regarding the Use of Diagnostic Kits for COVID-19
    • 3.4. Market Trends
      • 3.4.1. A Shift in Focus from Centralized Laboratories to Decentralized Point-Of-Care Testing
      • 3.4.2. An Upsurge in Validating and Developing Rapid POC Immunodiagnostic Tests to Facilitate Decentralized Testing
      • 3.4.3. Growing Trend of Incorporation of Artificial Intelligence (AI) in the COVID-19 Tests for Rapid and Efficient Diagnosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Coronavirus Diagnostics, by Type, Product Used, Infection Type, End-Users, Sample Type, Mode of Diagnosis and Region (value and price ) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global Coronavirus Diagnostics (Value)
      • 5.2.1. Global Coronavirus Diagnostics by: Type (Value)
        • 5.2.1.1. Molecular
        • 5.2.1.2. Serology
        • 5.2.1.3. Antigen-Based
      • 5.2.2. Global Coronavirus Diagnostics by: Product Used (Value)
        • 5.2.2.1. Instruments
        • 5.2.2.2. Reagents & Kits
      • 5.2.3. Global Coronavirus Diagnostics by: Infection Type (Value)
        • 5.2.3.1. HCoV-229E
        • 5.2.3.2. HCoV-OC43
        • 5.2.3.3. SARS-CoV
        • 5.2.3.4. HKU1-CoV
        • 5.2.3.5. MERS-CoV
      • 5.2.4. Global Coronavirus Diagnostics by: End-Users (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Public Health Labs
        • 5.2.4.3. Private or Commercial Labs
        • 5.2.4.4. Physician Labs
        • 5.2.4.5. Diagnostic Centers and Clinics
        • 5.2.4.6. Research Institutes
        • 5.2.4.7. Others
      • 5.2.5. Global Coronavirus Diagnostics by: Sample Type (Value)
        • 5.2.5.1. Nasopharyngeal (NP) Swab
        • 5.2.5.2. Oropharyngeal (OP) Swab
        • 5.2.5.3. Nasal Swab
      • 5.2.6. Global Coronavirus Diagnostics by: Mode of Diagnosis (Value)
        • 5.2.6.1. Point-of-Care (POC)
        • 5.2.6.2. Non-Point-of-Care (Non-PoC)
      • 5.2.7. Global Coronavirus Diagnostics Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Coronavirus Diagnostics (Price)
      • 5.3.1. Global Coronavirus Diagnostics by: Type (Price)
  • 6. Coronavirus Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bio-Rad Laboratories Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Beckman Coulter Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Becton, Dickinson, and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lonza Group AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hologic, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. QIAGEN (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline Biologicals SA (Belgium)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Perkin Elmer, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Neuberg Diagnostics (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. 1drop Inc. (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Veredus Laboratories (Hong Kong)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. ADT Biotech (Malaysia)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Quest Diagnostics (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. LabCorp (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Altona Diagnostics GmbH (Germany)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. BioMérieux SA (France)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
      • 6.4.19. Mylab Discovery Solutions Pvt Ltd. (India)
        • 6.4.19.1. Business Overview
        • 6.4.19.2. Products/Services Offerings
        • 6.4.19.3. Financial Analysis
        • 6.4.19.4. SWOT Analysis
  • 7. Global Coronavirus Diagnostics Sale, by Type, Product Used, Infection Type, End-Users, Sample Type, Mode of Diagnosis and Region (value and price ) (2027-2032)
    • 7.1. Introduction
    • 7.2. Global Coronavirus Diagnostics (Value)
      • 7.2.1. Global Coronavirus Diagnostics by: Type (Value)
        • 7.2.1.1. Molecular
        • 7.2.1.2. Serology
        • 7.2.1.3. Antigen-Based
      • 7.2.2. Global Coronavirus Diagnostics by: Product Used (Value)
        • 7.2.2.1. Instruments
        • 7.2.2.2. Reagents & Kits
      • 7.2.3. Global Coronavirus Diagnostics by: Infection Type (Value)
        • 7.2.3.1. HCoV-229E
        • 7.2.3.2. HCoV-OC43
        • 7.2.3.3. SARS-CoV
        • 7.2.3.4. HKU1-CoV
        • 7.2.3.5. MERS-CoV
      • 7.2.4. Global Coronavirus Diagnostics by: End-Users (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Public Health Labs
        • 7.2.4.3. Private or Commercial Labs
        • 7.2.4.4. Physician Labs
        • 7.2.4.5. Diagnostic Centers and Clinics
        • 7.2.4.6. Research Institutes
        • 7.2.4.7. Others
      • 7.2.5. Global Coronavirus Diagnostics by: Sample Type (Value)
        • 7.2.5.1. Nasopharyngeal (NP) Swab
        • 7.2.5.2. Oropharyngeal (OP) Swab
        • 7.2.5.3. Nasal Swab
      • 7.2.6. Global Coronavirus Diagnostics by: Mode of Diagnosis (Value)
        • 7.2.6.1. Point-of-Care (POC)
        • 7.2.6.2. Non-Point-of-Care (Non-PoC)
      • 7.2.7. Global Coronavirus Diagnostics Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Coronavirus Diagnostics (Price)
      • 7.3.1. Global Coronavirus Diagnostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Coronavirus Diagnostics: by Type(USD Million)
  • Table 2. Coronavirus Diagnostics Molecular , by Region USD Million (2019-2024)
  • Table 3. Coronavirus Diagnostics Serology , by Region USD Million (2019-2024)
  • Table 4. Coronavirus Diagnostics Antigen-Based , by Region USD Million (2019-2024)
  • Table 5. Coronavirus Diagnostics: by Product Used(USD Million)
  • Table 6. Coronavirus Diagnostics Instruments , by Region USD Million (2019-2024)
  • Table 7. Coronavirus Diagnostics Reagents & Kits , by Region USD Million (2019-2024)
  • Table 8. Coronavirus Diagnostics: by Infection Type(USD Million)
  • Table 9. Coronavirus Diagnostics HCoV-229E , by Region USD Million (2019-2024)
  • Table 10. Coronavirus Diagnostics HCoV-OC43 , by Region USD Million (2019-2024)
  • Table 11. Coronavirus Diagnostics SARS-CoV , by Region USD Million (2019-2024)
  • Table 12. Coronavirus Diagnostics HKU1-CoV , by Region USD Million (2019-2024)
  • Table 13. Coronavirus Diagnostics MERS-CoV , by Region USD Million (2019-2024)
  • Table 14. Coronavirus Diagnostics: by End-Users(USD Million)
  • Table 15. Coronavirus Diagnostics Hospitals , by Region USD Million (2019-2024)
  • Table 16. Coronavirus Diagnostics Public Health Labs , by Region USD Million (2019-2024)
  • Table 17. Coronavirus Diagnostics Private or Commercial Labs , by Region USD Million (2019-2024)
  • Table 18. Coronavirus Diagnostics Physician Labs , by Region USD Million (2019-2024)
  • Table 19. Coronavirus Diagnostics Diagnostic Centers and Clinics , by Region USD Million (2019-2024)
  • Table 20. Coronavirus Diagnostics Research Institutes , by Region USD Million (2019-2024)
  • Table 21. Coronavirus Diagnostics Others , by Region USD Million (2019-2024)
  • Table 22. Coronavirus Diagnostics: by Sample Type(USD Million)
  • Table 23. Coronavirus Diagnostics Nasopharyngeal (NP) Swab , by Region USD Million (2019-2024)
  • Table 24. Coronavirus Diagnostics Oropharyngeal (OP) Swab , by Region USD Million (2019-2024)
  • Table 25. Coronavirus Diagnostics Nasal Swab , by Region USD Million (2019-2024)
  • Table 26. Coronavirus Diagnostics: by Mode of Diagnosis(USD Million)
  • Table 27. Coronavirus Diagnostics Point-of-Care (POC) , by Region USD Million (2019-2024)
  • Table 28. Coronavirus Diagnostics Non-Point-of-Care (Non-PoC) , by Region USD Million (2019-2024)
  • Table 29. South America Coronavirus Diagnostics, by Country USD Million (2019-2024)
  • Table 30. South America Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 31. South America Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 32. South America Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 33. South America Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 34. South America Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 35. South America Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 36. Brazil Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 37. Brazil Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 38. Brazil Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 39. Brazil Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 40. Brazil Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 41. Brazil Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 42. Argentina Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 43. Argentina Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 44. Argentina Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 45. Argentina Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 46. Argentina Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 47. Argentina Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 48. Rest of South America Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 49. Rest of South America Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 50. Rest of South America Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 51. Rest of South America Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 52. Rest of South America Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 53. Rest of South America Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 54. Asia Pacific Coronavirus Diagnostics, by Country USD Million (2019-2024)
  • Table 55. Asia Pacific Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 56. Asia Pacific Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 57. Asia Pacific Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 58. Asia Pacific Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 59. Asia Pacific Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 60. Asia Pacific Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 61. China Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 62. China Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 63. China Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 64. China Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 65. China Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 66. China Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 67. Japan Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 68. Japan Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 69. Japan Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 70. Japan Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 71. Japan Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 72. Japan Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 73. India Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 74. India Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 75. India Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 76. India Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 77. India Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 78. India Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 79. South Korea Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 80. South Korea Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 81. South Korea Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 82. South Korea Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 83. South Korea Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 84. South Korea Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 85. Taiwan Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 86. Taiwan Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 87. Taiwan Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 88. Taiwan Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 89. Taiwan Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 90. Taiwan Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 91. Australia Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 92. Australia Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 93. Australia Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 94. Australia Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 95. Australia Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 96. Australia Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 97. Rest of Asia-Pacific Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 98. Rest of Asia-Pacific Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 99. Rest of Asia-Pacific Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 100. Rest of Asia-Pacific Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 101. Rest of Asia-Pacific Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 102. Rest of Asia-Pacific Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 103. Europe Coronavirus Diagnostics, by Country USD Million (2019-2024)
  • Table 104. Europe Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 105. Europe Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 106. Europe Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 107. Europe Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 108. Europe Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 109. Europe Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 110. Germany Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 111. Germany Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 112. Germany Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 113. Germany Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 114. Germany Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 115. Germany Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 116. France Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 117. France Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 118. France Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 119. France Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 120. France Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 121. France Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 122. Italy Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 123. Italy Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 124. Italy Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 125. Italy Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 126. Italy Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 127. Italy Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 128. United Kingdom Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 129. United Kingdom Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 130. United Kingdom Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 131. United Kingdom Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 132. United Kingdom Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 133. United Kingdom Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 134. Netherlands Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 135. Netherlands Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 136. Netherlands Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 137. Netherlands Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 138. Netherlands Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 139. Netherlands Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 140. Rest of Europe Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 141. Rest of Europe Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 142. Rest of Europe Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 143. Rest of Europe Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 144. Rest of Europe Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 145. Rest of Europe Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 146. MEA Coronavirus Diagnostics, by Country USD Million (2019-2024)
  • Table 147. MEA Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 148. MEA Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 149. MEA Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 150. MEA Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 151. MEA Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 152. MEA Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 153. Middle East Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 154. Middle East Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 155. Middle East Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 156. Middle East Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 157. Middle East Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 158. Middle East Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 159. Africa Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 160. Africa Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 161. Africa Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 162. Africa Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 163. Africa Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 164. Africa Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 165. North America Coronavirus Diagnostics, by Country USD Million (2019-2024)
  • Table 166. North America Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 167. North America Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 168. North America Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 169. North America Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 170. North America Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 171. North America Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 172. United States Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 173. United States Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 174. United States Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 175. United States Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 176. United States Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 177. United States Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 178. Canada Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 179. Canada Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 180. Canada Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 181. Canada Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 182. Canada Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 183. Canada Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 184. Mexico Coronavirus Diagnostics, by Type USD Million (2019-2024)
  • Table 185. Mexico Coronavirus Diagnostics, by Product Used USD Million (2019-2024)
  • Table 186. Mexico Coronavirus Diagnostics, by Infection Type USD Million (2019-2024)
  • Table 187. Mexico Coronavirus Diagnostics, by End-Users USD Million (2019-2024)
  • Table 188. Mexico Coronavirus Diagnostics, by Sample Type USD Million (2019-2024)
  • Table 189. Mexico Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2019-2024)
  • Table 190. Coronavirus Diagnostics: by Type(USD/Units)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Coronavirus Diagnostics: by Type(USD Million)
  • Table 211. Coronavirus Diagnostics Molecular , by Region USD Million (2027-2032)
  • Table 212. Coronavirus Diagnostics Serology , by Region USD Million (2027-2032)
  • Table 213. Coronavirus Diagnostics Antigen-Based , by Region USD Million (2027-2032)
  • Table 214. Coronavirus Diagnostics: by Product Used(USD Million)
  • Table 215. Coronavirus Diagnostics Instruments , by Region USD Million (2027-2032)
  • Table 216. Coronavirus Diagnostics Reagents & Kits , by Region USD Million (2027-2032)
  • Table 217. Coronavirus Diagnostics: by Infection Type(USD Million)
  • Table 218. Coronavirus Diagnostics HCoV-229E , by Region USD Million (2027-2032)
  • Table 219. Coronavirus Diagnostics HCoV-OC43 , by Region USD Million (2027-2032)
  • Table 220. Coronavirus Diagnostics SARS-CoV , by Region USD Million (2027-2032)
  • Table 221. Coronavirus Diagnostics HKU1-CoV , by Region USD Million (2027-2032)
  • Table 222. Coronavirus Diagnostics MERS-CoV , by Region USD Million (2027-2032)
  • Table 223. Coronavirus Diagnostics: by End-Users(USD Million)
  • Table 224. Coronavirus Diagnostics Hospitals , by Region USD Million (2027-2032)
  • Table 225. Coronavirus Diagnostics Public Health Labs , by Region USD Million (2027-2032)
  • Table 226. Coronavirus Diagnostics Private or Commercial Labs , by Region USD Million (2027-2032)
  • Table 227. Coronavirus Diagnostics Physician Labs , by Region USD Million (2027-2032)
  • Table 228. Coronavirus Diagnostics Diagnostic Centers and Clinics , by Region USD Million (2027-2032)
  • Table 229. Coronavirus Diagnostics Research Institutes , by Region USD Million (2027-2032)
  • Table 230. Coronavirus Diagnostics Others , by Region USD Million (2027-2032)
  • Table 231. Coronavirus Diagnostics: by Sample Type(USD Million)
  • Table 232. Coronavirus Diagnostics Nasopharyngeal (NP) Swab , by Region USD Million (2027-2032)
  • Table 233. Coronavirus Diagnostics Oropharyngeal (OP) Swab , by Region USD Million (2027-2032)
  • Table 234. Coronavirus Diagnostics Nasal Swab , by Region USD Million (2027-2032)
  • Table 235. Coronavirus Diagnostics: by Mode of Diagnosis(USD Million)
  • Table 236. Coronavirus Diagnostics Point-of-Care (POC) , by Region USD Million (2027-2032)
  • Table 237. Coronavirus Diagnostics Non-Point-of-Care (Non-PoC) , by Region USD Million (2027-2032)
  • Table 238. South America Coronavirus Diagnostics, by Country USD Million (2027-2032)
  • Table 239. South America Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 240. South America Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 241. South America Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 242. South America Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 243. South America Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 244. South America Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 245. Brazil Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 246. Brazil Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 247. Brazil Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 248. Brazil Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 249. Brazil Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 250. Brazil Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 251. Argentina Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 252. Argentina Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 253. Argentina Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 254. Argentina Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 255. Argentina Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 256. Argentina Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 257. Rest of South America Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 258. Rest of South America Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 259. Rest of South America Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 260. Rest of South America Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 261. Rest of South America Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 262. Rest of South America Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 263. Asia Pacific Coronavirus Diagnostics, by Country USD Million (2027-2032)
  • Table 264. Asia Pacific Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 265. Asia Pacific Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 266. Asia Pacific Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 267. Asia Pacific Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 268. Asia Pacific Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 269. Asia Pacific Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 270. China Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 271. China Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 272. China Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 273. China Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 274. China Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 275. China Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 276. Japan Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 277. Japan Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 278. Japan Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 279. Japan Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 280. Japan Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 281. Japan Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 282. India Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 283. India Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 284. India Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 285. India Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 286. India Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 287. India Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 288. South Korea Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 289. South Korea Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 290. South Korea Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 291. South Korea Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 292. South Korea Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 293. South Korea Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 294. Taiwan Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 295. Taiwan Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 296. Taiwan Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 297. Taiwan Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 298. Taiwan Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 299. Taiwan Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 300. Australia Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 301. Australia Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 302. Australia Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 303. Australia Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 304. Australia Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 305. Australia Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 306. Rest of Asia-Pacific Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 307. Rest of Asia-Pacific Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 308. Rest of Asia-Pacific Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 309. Rest of Asia-Pacific Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 310. Rest of Asia-Pacific Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 311. Rest of Asia-Pacific Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 312. Europe Coronavirus Diagnostics, by Country USD Million (2027-2032)
  • Table 313. Europe Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 314. Europe Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 315. Europe Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 316. Europe Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 317. Europe Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 318. Europe Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 319. Germany Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 320. Germany Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 321. Germany Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 322. Germany Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 323. Germany Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 324. Germany Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 325. France Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 326. France Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 327. France Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 328. France Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 329. France Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 330. France Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 331. Italy Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 332. Italy Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 333. Italy Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 334. Italy Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 335. Italy Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 336. Italy Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 337. United Kingdom Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 338. United Kingdom Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 339. United Kingdom Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 340. United Kingdom Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 341. United Kingdom Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 342. United Kingdom Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 343. Netherlands Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 344. Netherlands Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 345. Netherlands Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 346. Netherlands Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 347. Netherlands Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 348. Netherlands Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 349. Rest of Europe Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 350. Rest of Europe Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 351. Rest of Europe Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 352. Rest of Europe Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 353. Rest of Europe Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 354. Rest of Europe Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 355. MEA Coronavirus Diagnostics, by Country USD Million (2027-2032)
  • Table 356. MEA Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 357. MEA Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 358. MEA Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 359. MEA Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 360. MEA Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 361. MEA Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 362. Middle East Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 363. Middle East Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 364. Middle East Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 365. Middle East Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 366. Middle East Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 367. Middle East Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 368. Africa Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 369. Africa Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 370. Africa Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 371. Africa Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 372. Africa Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 373. Africa Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 374. North America Coronavirus Diagnostics, by Country USD Million (2027-2032)
  • Table 375. North America Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 376. North America Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 377. North America Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 378. North America Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 379. North America Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 380. North America Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 381. United States Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 382. United States Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 383. United States Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 384. United States Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 385. United States Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 386. United States Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 387. Canada Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 388. Canada Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 389. Canada Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 390. Canada Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 391. Canada Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 392. Canada Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 393. Mexico Coronavirus Diagnostics, by Type USD Million (2027-2032)
  • Table 394. Mexico Coronavirus Diagnostics, by Product Used USD Million (2027-2032)
  • Table 395. Mexico Coronavirus Diagnostics, by Infection Type USD Million (2027-2032)
  • Table 396. Mexico Coronavirus Diagnostics, by End-Users USD Million (2027-2032)
  • Table 397. Mexico Coronavirus Diagnostics, by Sample Type USD Million (2027-2032)
  • Table 398. Mexico Coronavirus Diagnostics, by Mode of Diagnosis USD Million (2027-2032)
  • Table 399. Coronavirus Diagnostics: by Type(USD/Units)
  • Table 400. Research Programs/Design for This Report
  • Table 401. Key Data Information from Secondary Sources
  • Table 402. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Coronavirus Diagnostics: by Type USD Million (2019-2024)
  • Figure 5. Global Coronavirus Diagnostics: by Product Used USD Million (2019-2024)
  • Figure 6. Global Coronavirus Diagnostics: by Infection Type USD Million (2019-2024)
  • Figure 7. Global Coronavirus Diagnostics: by End-Users USD Million (2019-2024)
  • Figure 8. Global Coronavirus Diagnostics: by Sample Type USD Million (2019-2024)
  • Figure 9. Global Coronavirus Diagnostics: by Mode of Diagnosis USD Million (2019-2024)
  • Figure 10. South America Coronavirus Diagnostics Share (%), by Country
  • Figure 11. Asia Pacific Coronavirus Diagnostics Share (%), by Country
  • Figure 12. Europe Coronavirus Diagnostics Share (%), by Country
  • Figure 13. MEA Coronavirus Diagnostics Share (%), by Country
  • Figure 14. North America Coronavirus Diagnostics Share (%), by Country
  • Figure 15. Global Coronavirus Diagnostics: by Type USD/Units (2019-2024)
  • Figure 16. Global Coronavirus Diagnostics share by Players 2024 (%)
  • Figure 17. Global Coronavirus Diagnostics share by Players (Top 3) 2024(%)
  • Figure 18. Global Coronavirus Diagnostics share by Players (Top 5) 2024(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2024
  • Figure 22. Bio-Rad Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Bio-Rad Laboratories Inc. (United States) Revenue: by Geography 2024
  • Figure 24. Beckman Coulter Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Beckman Coulter Inc. (United States) Revenue: by Geography 2024
  • Figure 26. Becton, Dickinson, and Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Becton, Dickinson, and Company (United States) Revenue: by Geography 2024
  • Figure 28. Lonza Group AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Lonza Group AG (Switzerland) Revenue: by Geography 2024
  • Figure 30. Hologic, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Hologic, Inc. (United States) Revenue: by Geography 2024
  • Figure 32. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 33. QIAGEN (Germany) Revenue: by Geography 2024
  • Figure 34. GlaxoSmithKline Biologicals SA (Belgium) Revenue, Net Income and Gross profit
  • Figure 35. GlaxoSmithKline Biologicals SA (Belgium) Revenue: by Geography 2024
  • Figure 36. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 37. Abbott Laboratories (United States) Revenue: by Geography 2024
  • Figure 38. Perkin Elmer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Perkin Elmer, Inc. (United States) Revenue: by Geography 2024
  • Figure 40. Neuberg Diagnostics (India) Revenue, Net Income and Gross profit
  • Figure 41. Neuberg Diagnostics (India) Revenue: by Geography 2024
  • Figure 42. 1drop Inc. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 43. 1drop Inc. (Switzerland) Revenue: by Geography 2024
  • Figure 44. Veredus Laboratories (Hong Kong) Revenue, Net Income and Gross profit
  • Figure 45. Veredus Laboratories (Hong Kong) Revenue: by Geography 2024
  • Figure 46. ADT Biotech (Malaysia) Revenue, Net Income and Gross profit
  • Figure 47. ADT Biotech (Malaysia) Revenue: by Geography 2024
  • Figure 48. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 49. Quest Diagnostics (United States) Revenue: by Geography 2024
  • Figure 50. LabCorp (United States) Revenue, Net Income and Gross profit
  • Figure 51. LabCorp (United States) Revenue: by Geography 2024
  • Figure 52. Altona Diagnostics GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 53. Altona Diagnostics GmbH (Germany) Revenue: by Geography 2024
  • Figure 54. BioMérieux SA (France) Revenue, Net Income and Gross profit
  • Figure 55. BioMérieux SA (France) Revenue: by Geography 2024
  • Figure 56. Mylab Discovery Solutions Pvt Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 57. Mylab Discovery Solutions Pvt Ltd. (India) Revenue: by Geography 2024
  • Figure 58. Global Coronavirus Diagnostics: by Type USD Million (2027-2032)
  • Figure 59. Global Coronavirus Diagnostics: by Product Used USD Million (2027-2032)
  • Figure 60. Global Coronavirus Diagnostics: by Infection Type USD Million (2027-2032)
  • Figure 61. Global Coronavirus Diagnostics: by End-Users USD Million (2027-2032)
  • Figure 62. Global Coronavirus Diagnostics: by Sample Type USD Million (2027-2032)
  • Figure 63. Global Coronavirus Diagnostics: by Mode of Diagnosis USD Million (2027-2032)
  • Figure 64. South America Coronavirus Diagnostics Share (%), by Country
  • Figure 65. Asia Pacific Coronavirus Diagnostics Share (%), by Country
  • Figure 66. Europe Coronavirus Diagnostics Share (%), by Country
  • Figure 67. MEA Coronavirus Diagnostics Share (%), by Country
  • Figure 68. North America Coronavirus Diagnostics Share (%), by Country
  • Figure 69. Global Coronavirus Diagnostics: by Type USD/Units (2027-2032)
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche AG (Switzerland)
  • Bio-Rad Laboratories Inc. (United States)
  • Beckman Coulter Inc. (United States)
  • Becton, Dickinson, and Company (United States)
  • Lonza Group AG (Switzerland)
  • Hologic, Inc. (United States)
  • QIAGEN (Germany)
  • GlaxoSmithKline Biologicals SA (Belgium)
  • Abbott Laboratories (United States)
  • Perkin Elmer, Inc. (United States)
  • Neuberg Diagnostics (India)
  • 1drop Inc. (Switzerland)
  • Veredus Laboratories (Hong Kong)
  • ADT Biotech (Malaysia)
  • Quest Diagnostics (United States)
  • LabCorp (United States)
  • altona Diagnostics GmbH (Germany)
  • bioMérieux SA (France)
  • Mylab Discovery Solutions Pvt Ltd. (India)
Additional players considered in the study are as follows:
Aldatu Biosciences (United States) , Quidel Corporation (United States) , Luminex Corporation (United States) , Cepheid Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2025 231 Pages 72 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Coronavirus Diagnostics Quantitative research analysis
Global Coronavirus Diagnostics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as F. Hoffmann-La Roche AG (Switzerland), Bio-Rad Laboratories Inc. (United States), Beckman Coulter Inc. (United States), Becton, Dickinson, and Company (United States), Lonza Group AG (Switzerland), Hologic, Inc. (United States), QIAGEN (Germany), GlaxoSmithKline Biologicals SA (Belgium), Abbott Laboratories (United States), Perkin Elmer, Inc. (United States), Neuberg Diagnostics (India), 1drop Inc. (Switzerland), Veredus Laboratories (Hong Kong), ADT Biotech (Malaysia), Quest Diagnostics (United States), LabCorp (United States), altona Diagnostics GmbH (Germany), bioMérieux SA (France) and Mylab Discovery Solutions Pvt Ltd. (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"A Shift in Focus from Centralized Laboratories to Decentralized Point-Of-Care Testing " is seen as one of major influencing trends for Coronavirus Diagnostics Market during projected period 2024-2032.
The Coronavirus Diagnostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Coronavirus Diagnostics Report?

Have a Query? Click Here

Other Related Reports

Freestanding Emergency Department Comprehensive Study by Type (Ophthalmology, Internal Medicine, Otolaryngology, Others), End users (Hospital, Clinic, Others), Ownership (Off-Campus Emergency Departm...
$ 3650
Telemental Health Comprehensive Study by Type (Telepsychology, Telepsychiatry, Telebehavioral Health), Application (Inpatient Hospital Treatment Services, Outpatient Counselling, Emergency Mental Hea...
$ 3750
Online Fitness Course Comprehensive Study by Type (Pay by Course, Pay by Time), Application (Adults, Children), Device (PC, Mobile, Tablet) Players and Region - Global Market Outlook to 2027
$ 3500
Platelet Function Testing Comprehensive Study by Type (Systems, Reagents, Accessories), Application (Research, Pharmaceutical Development, Others), Testing Type (Light Transmission Aggregometry (LTA)...
$ 3750
CPAP Pillows Comprehensive Study by Type (Memory Foam, Buckwheat, Others), Application (Hospitals, Clinics, Home, Health Care Institutions), Configuration (Hose Tether, Without Hose Tether), Distribu...
$ 3450
Pediatric Clinical Trials Comprehensive Study by Type (Phase I, Phase II, Phase III, Phase IV), Application (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, Others), Study Design (Inte...
$ 3350